Elizabeth M. Whitley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elizabeth M. Whitley has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Alan F. Humphreys
Center for Comparative Medicine, Baylor College of Medicine, Houston, TX
1 shared publicationAlberto Mendoza
Vet Tech Institute of Houston, Houston, TX
1 shared publicationAmanda L. Trimble
Center for Laboratory Animal Medicine and Care, The University of Texas Health Science Center at Houston, Houston, TX
1 shared publication- Brenda Melendez
Department of Genomic Medicine
1 shared publication - Collene Jeter
The University of Texas MD Anderson Cancer Center 14 Division of VP, Research, Department of Epigenetics and Molecular Carcinogenesis Houston, Texas
1 shared publication Dawn L. Samuels
Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication
Latest Publications
- Open Access
- 4 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (6)
Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome–associated MSH2-deficient endometrial cancer
Lynch syndrome (LS), caused by inherited mutations in DNA mismatch repair genes, including MSH2 , carries a 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, mechanisms driving LS-associated EC (LS-EC) remain unclear. We investigated MSH2 loss in EC pathogenesis using a mouse model ( PR-Cre Msh2 LoxP/LoxP , abbreviated Msh2KO), primary cell lines, human tissues, and human EC cells with isogenic MSH2 knockdown. By 8 months, 58% of Msh2KO mice developed endometrial atypical hyperplasia (AH), a precancerous lesion. At 12–16 months, 50% of Msh2KO mice exhibited either AH or ECs with histologic similarities to human LS-ECs. Transcriptomic profiling of EC from Msh2KO mice revealed mitochondrial dysfunction–related pathway changes. Subsequent studies in vitro and in vivo revealed mitochondrial dysfunction based on 2 mechanisms: mitochondrial content reduction and structural disruptions in retained mitochondria. Human LS-ECs also exhibited mitochondrial content reduction compared with non-LS-ECs. Functional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression. These findings identified mitochondrial dysfunction and metabolic disruption as consequences of MSH2 deficiency in EC. Mitochondrial and metabolic aberrations should be evaluated as biomarkers for endometrial carcinogenesis or risk stratification and represent potential targets for cancer interception in women with LS.
- 4 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (6)
Open AccessMitochondrial defects and metabolic vulnerabilities in Lynch syndrome–associated MSH2-deficient endometrial cancer
Lynch syndrome (LS), caused by inherited mutations in DNA mismatch repair genes, including MSH2 , carries a 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, mechanisms driving LS-associated EC (LS-EC) remain unclear. We investigated MSH2 loss in EC pathogenesis using a mouse model ( PR-Cre Msh2 LoxP/LoxP , abbreviated Msh2KO), primary cell lines, human tissues, and human EC cells with isogenic MSH2 knockdown. By 8 months, 58% of Msh2KO mice developed endometrial atypical hyperplasia (AH), a precancerous lesion. At 12–16 months, 50% of Msh2KO mice exhibited either AH or ECs with histologic similarities to human LS-ECs. Transcriptomic profiling of EC from Msh2KO mice revealed mitochondrial dysfunction–related pathway changes. Subsequent studies in vitro and in vivo revealed mitochondrial dysfunction based on 2 mechanisms: mitochondrial content reduction and structural disruptions in retained mitochondria. Human LS-ECs also exhibited mitochondrial content reduction compared with non-LS-ECs. Functional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression. These findings identified mitochondrial dysfunction and metabolic disruption as consequences of MSH2 deficiency in EC. Mitochondrial and metabolic aberrations should be evaluated as biomarkers for endometrial carcinogenesis or risk stratification and represent potential targets for cancer interception in women with LS.
- Open Access
- 1 March 2022
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 259 (S2) , 1-4
Pathology in Practice
In collaboration with the American College of Veterinary Pathologists
- 1 March 2022
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 259 (S2) , 1-4
Open AccessPathology in Practice
In collaboration with the American College of Veterinary Pathologists